Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Subdued P/S Might Signal An Opportunity

Simply Wall St.01-20 18:24

You may think that with a price-to-sales (or "P/S") ratio of 2.4x Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a stock worth checking out, seeing as almost half of all the Life Sciences companies in the...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605117984?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/5122000-choice1-main-header/1585186630654","is_english":true,"pubTime":"2026-01-20 18:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605117984","market":"hk","top_or_hot":-1,"title":"Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Subdued P/S Might Signal An Opportunity","media":"Simply Wall St.","content":"<div>\n<p>You may think that with a price-to-sales (or \"P/S\") ratio of 2.4x Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a stock worth checking out, seeing as almost half of all the Life Sciences companies in the...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lfcr/lifecore-biomedical/news/lifecore-biomedical-incs-nasdaqlfcr-subdued-ps-might-signal\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Subdued P/S Might Signal An Opportunity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLifecore Biomedical, Inc.'s (NASDAQ:LFCR) Subdued P/S Might Signal An Opportunity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-20 18:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lfcr/lifecore-biomedical/news/lifecore-biomedical-incs-nasdaqlfcr-subdued-ps-might-signal><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>You may think that with a price-to-sales (or \"P/S\") ratio of 2.4x Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a stock worth checking out, seeing as almost half of all the Life Sciences companies in the...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lfcr/lifecore-biomedical/news/lifecore-biomedical-incs-nasdaqlfcr-subdued-ps-might-signal\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LFCR","symbol_name":"LIFECORE BIOMEDICAL INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lfcr/lifecore-biomedical/news/lifecore-biomedical-incs-nasdaqlfcr-subdued-ps-might-signal","article_id":"2605117984","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/5122000-choice1-main-header/1585186630654"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lfcr/lifecore-biomedical/news/lifecore-biomedical-incs-nasdaqlfcr-subdued-ps-might-signal","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2605117984","pubTimestamp":1768904678,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"You may think that with a price-to-sales (or \"P/S\") ratio of 2.4x Lifecore Biomedical, Inc. ( NASDAQ:LFCR ) is a stock...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LFCR":"LIFECORE BIOMEDICAL INC","USAW.SI":"AMZN 3xLongSG261006","JEPQ":"JPMorgan Nasdaq Equity Premium Income ETF","QYLD":"纳斯达克100 Covered Call ETF-Global X",".IXIC":"NASDAQ Composite","QLD":"2倍做多纳斯达克100指数ETF-ProShares","QYLG":"Nasdaq 100 Covered Call & Growth ETF","BK4212":"包装食品与肉类","QQQE":"Direxion NASDAQ-100 Equal Weighted Index Shares","GPIQ":"GOLDMAN SACHS NASDAQ 100 CORE PREMIUM INCOME ETF","QQQY":"Defiance Nasdaq 100 Enhanced Options & 0DTE Income ETF","TQQQ":"纳指三倍做多ETF","TSYW.SI":"TESLA 3xLongSG261006","SQQQ":"纳指三倍做空ETF","BK4121":"生命科学工具和服务","USJW.SI":"ALPHAB 3xLongSG261006","QID":"两倍做空纳斯达克指数ETF-ProShares","QQQJ":"Invesco NASDAQ Next Gen 100 ETF","NVIW.SI":"NVDA 3xLongSG261006","QQQM":"NASDAQ100指数ETF-Invesco","PSQ":"做空纳斯达克100指数ETF-ProShares"},"translate_title":"Lifecore Biomedical，Inc.（纳斯达克：LFCR）低迷的市盈率可能预示着一个机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TSYW.SI":0.6,"QQQM":0.6,"LFCR":1.5,"NVIW.SI":0.6,"USJW.SI":0.6,"GPIQ":0.6,"QYLD":0.6,"QLD":0.6,"TQQQ":0.6,"QYLG":0.6,"QID":0.6,"JEPQ":0.6,"QQQJ":0.6,"NQmain":0.6,"PSQ":0.6,"USAW.SI":0.6,".IXIC":1.5,"QQQY":0.6,"MNQmain":0.6,"SQQQ":0.6,"QQQE":0.6},"content_text":"You may think that with a price-to-sales (or \"P/S\") ratio of 2.4x Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a stock worth checking out, seeing as almost half of all the Life Sciences companies in the United States have P/S ratios greater than 3.7x and even P/S higher than 7x aren't out of the ordinary.   Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S.    AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.  Check out our latest analysis for Lifecore Biomedical NasdaqGS:LFCR Price to Sales Ratio vs Industry January 20th 2026Advertisement How Has Lifecore Biomedical Performed Recently?  Recent times haven't been great for Lifecore Biomedical as its revenue has been rising slower than most other companies.   It seems that many are expecting the uninspiring revenue performance to persist, which has repressed the growth of the P/S ratio.  If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price.      If you'd like to see what analysts are forecasting going forward, you should check out our free report on Lifecore Biomedical.  What Are Revenue Growth Metrics Telling Us About The Low P/S?   In order to justify its P/S ratio, Lifecore Biomedical would need to produce sluggish growth that's trailing the industry.   Taking a look back first, we see that there was hardly any revenue growth to speak of for the company over the past year.   Regardless, revenue has managed to lift by a handy 16% in aggregate from three years ago, thanks to the earlier period of growth.  So it appears to us that the company has had a mixed result in terms of growing revenue over that time.     Looking ahead now, revenue is anticipated to climb by 5.8% per annum during the coming three years according to the four analysts following the company.  With the industry predicted to deliver 6.5% growth  each year, the company is positioned for a comparable revenue result.  With this information, we find it odd that Lifecore Biomedical is trading at a P/S lower than the industry.  It may be that most investors are not convinced the company can achieve future growth expectations.    The Final Word  Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.  We've seen that Lifecore Biomedical currently trades on a lower than expected P/S since its forecast growth is in line with the wider industry.  The low P/S could be an indication that the revenue growth estimates are being questioned by the market.  However, if you agree with the analysts' forecasts, you may be able to pick up the stock at an attractive price.      Before you settle on your opinion, we've discovered 2 warning signs for Lifecore Biomedical that you should be aware of.   It's important to make sure you look for a great company, not just the first idea you come across. So if growing profitability aligns with your idea of a great company, take a peek at this free list of interesting companies with strong recent earnings growth (and a low P/E). New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605117984","isCrawlerRequest":true}